Hypertension is a chronic condition characterized by persistently elevated arterial blood pressure. It is often asymptomatic but significantly increases the risk of stroke, myocardial infarction, heart failure, kidney disease, and premature death. Management combines lifestyle modification and antihypertensive medications.
A case report describes eight-and-a-half syndrome in a 71-year-old man with hypertension and ischemic heart disease who presented with acute neurological deficits. MRI revealed an acute pontine infarction causing the characteristic triad of horizontal gaze palsy, internuclear ophthalmoplegia, and facial weakness.
The U.S. cardiovascular drugs market is projected to reach $37.03 billion by 2035, growing at a CAGR of 2.68%. Europe's anticoagulants market is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22%.
Baxfendy was approved in the US for hypertension in adults not adequately controlled on other antihypertensive medicines. The approval was based on Phase III BaxHTN results showing significant systolic blood pressure reductions.
CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
Alnylam Pharmaceuticals entered a $1.23 billion discovery collaboration with Tenaya Therapeutics to identify up to 15 novel genetic targets for heart disease. The agreement includes $10 million upfront and up to $1.13 billion in milestone payments.
The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
The FDA said one pivotal trial plus confirmatory evidence will become the default standard for approval of most new drugs. The shift could extend beyond rare diseases to common conditions affecting millions.
Experts discuss balancing efficacy and safety in BTK inhibitor plus venetoclax combination therapy for CLL, including BTK lead-in strategies to reduce tumor lysis syndrome risk and the benefits of all-oral fixed-duration regimens.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07614724 |
Salt Sensitivity Evaluation Via N-of-1 Trials (SENSE-Salt) |
NOT_YET_RECRUITING | NA |
| NCT07614659 |
Uppsala Self-Screening of Cardiovascular Health (U-SCREEN) |
RECRUITING | NA |
| NCT07609875 |
A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension |
NOT_YET_RECRUITING | PHASE1 |
| NCT07607275 |
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension |
NOT_YET_RECRUITING | PHASE4 |
| NCT07606183 |
Effects of Different Forms of a Natural Heart Hormone on Blood Pressure and Fluid Balance in Healthy Volunteers |
COMPLETED | EARLY_PHASE1 |
| NCT07603583 |
Assessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension |
RECRUITING | |
| NCT07603037 |
EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure |
NOT_YET_RECRUITING | NA |
| NCT07598968 |
Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers |
COMPLETED | PHASE1 |
| NCT07595016 |
Clinical Validation of the Blood Pressure Measuring Device Withings BPM Pro 2 in Pregnancy and Pre-eclampsia |
RECRUITING | NA |
| NCT07594808 |
Using Mobile Stress Management to Reduce Hypertension in African American Men |
NOT_YET_RECRUITING | PHASE2 |
